Functions of 55 Newfound Proteins and Their Medicinal Application in the Treatment and Prevention of Disease
OwnerKieu Hoanginventor
Life of this patent
Estimating the term…
Abstract
The invention relates to 55 newly discovered proteins, which are present in isolated purified protein complexes, derived medicinal products, recombinant DNA, engineered DNA, cDNA, monoclonal and natural products or synthesized products as part of nutrition, food, and/or supplemental products and their applications.
Claims37
A method of treating or preventing disease and infection in a mammal comprising, administering to the mammal a composition, compound, or solution containing an effective amount of at least one isolated purified plasma product selected from the group consisting of:
- cryoprecipitate;
- fraction III;
- fraction III-II;
- fraction IV;
- prothrombin;
- human factor VIII;
- human fibrinogen;
- human immunoglobulin;
- human thrombin;
- human albumin;
- and
- transferrin.
A method of treating human immunodeficiency virus comprising, administering to an individual infected with HIV a composition, compound, or solution containing an effective amount of a blood plasma product comprising purified factor II, purified factor VII, and purified factor X.
A method of treating human immunodeficiency virus comprising, administering to an individual infected with HIV a composition, compound, or solution containing an effective amount of a blood plasma product comprising purified antithrombin III and at least one protein defined by an amino acid sequence selected from the group consisting of:
- SEQ ID NO:
- 21;
- SEQ ID NO:
- 22;
- SEQ ID NO:
- 23;
- SEQ ID NO:
- 24;
- SEQ ID NO:
- 25;
- SEQ ID NO:
- 26;
- SEQ ID NO:
- 27;
- SEQ ID NO:
- 48;
- SEQ ID NO:
- 49;
- and
- SEQ ID NO:
- 50.
A method of treating hepatitis C virus in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a blood plasma concentrate containing:
- CP 98 kDa;
- CP Ceruloplasmin;
- KRT2 Keratin, type II cytoskeletal 2 epidermal;
- APOA1;
- human albumin;
- transferrin;
- and
- haptoglobin.
A method of treating hepatitis C virus in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a blood plasma concentrate comprising factor II, factor VII, factor IX, and factor X.
A method of treating hepatitis B virus in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a blood plasma concentrate comprising:
- CP 98 kDa;
- CP Reuloplasmin;
- KRT2 Keratin, type II cytoskeletal epidermal;
- a protein defined by amino acid sequence SEQ ID NO:
- 22;
- a protein defined by amino acid sequence SEQ ID NO:
- 23;
- a protein defined by amino acid sequence SEQ ID NO:
- 24;
- a protein defined by amino acid sequence SEQ ID NO:
- 25;
- APOA1;
- human albumin;
- transferrin;
- vimentin;
- and
- haptoglobin.
A method of treating hepatitis B virus in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a blood plasma concentrate derived from fraction III IVIG, the blood plasma concentrate derived from fraction III IVIG comprising TF serotransferrin.
A method of treating influenza in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a purified plasma product, wherein said purified plasma product is selected from the group consisting of:
- a first protein concentrate comprising proteins CP 98 kDa, CP Ceruloplasmin, KRT2 Keratin-type II cytoskeletal 2 epidermal, APOA1, human albumin, transferrin, vimentin, and haptoglobin;
- and
- a prothrombin complex protein concentrate comprising proteins factor II, factor VII, factor IX, and factor X.
A method of treating diabetes mellitus in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of a purified plasma product, wherein the purified plasma product is selected from the group consisting of:
- a first protein concentrate comprising protein 1CP 98 kDa, wherein protein 1CP98 kDa containing Nup98 and Nup96;
- a second protein concentrate comprising transferrin;
- and
- a third protein concentrate comprising CP 98 kDa, CP Ceruloplasmin, KRT2 Keratin type II cytoskeletal 2 epidermal, APOA1, human albumin, transferrin, vimentin, and haptoglobin.
A method of treating and preventing atherosclerosis and related cardiovascular diseases comprising, administering to an individual a daily dose of a composition, compound, or solution containing an effective amount of purified Apolipoprotein A-1 for at least 16 weeks.
A method of treating cancer in a mammal comprising, administering to said mammal a composition, compound, or solution containing an effective amount of at least one plasma product selected from the group consisting of:
- high concentrated fibrinogen, enriched a1at, thrombin, and AFOD.
A method of treating cancer in a mammal comprising, administering to a mammal a composition, compound, or solution containing an effective amount of high concentrated fibrinogen enriched a1at thrombin and AFOD.
A method of treating Parkinson's disease in a mammal comprising:
- a) performing a PET/CT scan on said mammal to determine baseline brain function;
- b) intravenously administering an effective daily dose of a ApoAI to said mammal;
- c) performing at least one additional PET/CT scan;
- d) determining whether brain signal function has improved in a time period between performing the at least one additional PET/CT scan and the previous PET/CT scan;
- and
- e) discontinuing intravenous administration of ApoAI to said mammal once it is determined that brain signal function has not improved in the time period between performing the at least one additional PET/CT scan and the previous PET/CT scan.
Dependencies are inferred from the claim text.